In this episode of Structural Heart Talks, Todd Brinton, MD, Chief Scientific Officer & CVP, Advanced Technology at Edwards Lifesciences, discusses Edwards’ vision of future innovative technologies that elevate patient care and expand the possibilities of structural heart therapies. Brinton reflects on his journey from biomedical engineering to pioneering roles in MedTech, including his work at Shockwave Medical, and shares how these experiences shaped his mission to create impactful technologies for patients worldwide.

The conversation dives deep into Edwards’ evolving focus on structural heart failure and non-valvular structural heart therapies, emphasizing investigational programs that challenge traditional approaches and push the boundaries of interventional cardiology. Brinton highlights how Edwards fosters a mission-driven culture of collaboration, uniting engineering, clinical expertise, and market insights to tackle some of the most complex challenges in cardiac care.

The episode also underscores the transformative role of mentorship in Brinton’s career and his commitment to paying it forward by empowering others in the MedTech space. Drawing on personal stories, Brinton illustrates how embracing failure and leveraging diverse perspectives have driven innovation at Edwards, paving the way for new therapies that can improve care for patients globally.

* Please note that this episode was recorded before the sale of Edwards’ Critical Care business unit to BD, which closed on Sept 3, 2024.

Thank you to Integer for sponsoring this episode of Structural Heart Talks. To learn more about how Integer supports medical device companies, visit www.Integer.net.

Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

Todd Brinton shares lessons on mentorship, Edwards’ culture and advancing heart failure innovation

In this episode of DeviceTalks Weekly, we’ll hear how Perimeter Medical Imaging AI hopes to help surgeons get a clearer picture of whether they removed all cancerous tissue in a surgical procedure. CEO Adrian Mendes explains why 20% of patients who have undergone a lumpectomy must undergo a second operation to remove cancerous tissue that had been missed. Perimeter recently released the positive results from its pivotal study showing it more effectively addressed residual cancer at the surgical margin during surgery as compared to current standard methods. The company is planning to file a PMA with the FDA. Mendes also talks with Host Tom Salemi about his path from the technology industry into running an OCT and AI company targeting oncology.

Perimeter Medical Imaging AI sponsored this episode of the DeviceTalks Weekly Podcast. For more information go to https://perimetermed.com/

MedTech CEO Paul Grand joins Tom and MassDevice Editor Chris Newmarker for this week’s Newmarker’s Newsmakers - Capstan Medical, Cala Health, Anteris Technologies, MedTech M&A and top stories.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

How Perimeter Medical hopes to use OCT & AI to boost surgeon confidence & patient peace of mind

In this episode of AbbottTalks, Kartik Sundareswaran, PhD, divisional VP, global clinical and regulatory affairs, Abbott Heart Failure, discusses Abbott’s pioneering work in heart failure care, focusing on technologies that improve outcomes and empower earlier interventions.

Sundareswaran’s path to MedTech began with a shift from computer engineering to biomedical research, where his early work studying blood flow patterns in children with congenital heart disease sparked a passion for solving cardiovascular challenges. This passion led him to roles at Thoratec, St. Jude Medical, and ultimately Abbott, where he has spent years advancing heart failure care.

The conversation highlights Abbott’s CardioMEMS™ Heart Failure System, a device enabling remote pulmonary artery pressure monitoring to reduce hospitalizations, and the HeartMate 3 LVAD, which provides life-extending support for patients with advanced heart failure. Sundareswaran also discusses the new TEAM-HF clinical trial, which combines CardioMEMS and HeartMate 3 to identify patients earlier and deliver timely, effective interventions.

This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Sundareswaran envisions TEAM-HF & earlier interventions to redefine heart failure outcomes

In our final 2024 episode of the DeviceTalks Weekly podcast, ResMed CEO Mick Farrell shares the company’s strategy for reaching the billions of people who need help sleeping, breathing and remaining healthy. He talks with Host Tom Salemi about the company’s connectivity capabilities, response to wearable technology, and its take on a rival’s recall.

This episode is sponsored by Aptyx. Go to www.Aptyx.com to learn more.

We’ll also bring you the Newsmakers of 2024 brought to you by DeviceTalks Managing Editor Kayleen Brown as well as our Editorial Team - Editor Chris Newmarker, Senior Editor Danielle Kirsh, Associate Editor Sean Whooley, and Jim Hammerand, managing editor of Medical Design and Outsourcing.

Thank you for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network on any major podcast player.

CEO Mick Farrell on how ResMed keeps on the leading edge of innovation; Our 2024’s Top Newsmakers

In 2024, only months before the world lost Dr. Nick Hopkins, Host John Murray, sat down with Dr. Hopkins to discuss his innovative treatments in stroke care, the necessity of collaboration and partnerships to advance research and clinical care, and the importance of mentorship and training the next generation of neurosurgeons.
 
In this special memorial episode, we hear Dr. Hopkins reflect on “not doing everything by the book, but looking around to ask: is there a better way than what’s in the book?” He shares his philosophy on embracing and learning from mistakes that have fueled advancements in neurovascular methodologies and inspired a culture of openness in the medical community. 
 
A champion of mentorship, Dr. Hopkins has acted as a guiding force for numerous professionals, shaping the future of neurovascular surgery. The episode also delves into the ethical and moral compass that underlies Dr. Hopkins’ work, reaffirming the profound humanity that anchors his approach to both his profession and personal life.
 
To honor the depth of Dr. Hopkins’ legacy, we hear directly from many of his mentees and fellows, including Dr. Adnan Siddiqui, Dr. Ricardo Hanel, Dr. Chuck Kerber, Dr. J. Mocco, Dr. Qureshi, Dr. Raphael Rodriguez, Dr. Demetrius Lopes, and Dr. Ajay Wakhlo on the personal and professional impact he has had on their lives and careers.

Thank you to Zeus for sponsoring this episode of Neuro Innovation Talks. To learn more about how Zeus supports medical device companies, visit: www.zeusinc.com.

Special thanks to Dr. Hopkins’s mentees and fellows who shared their stories and to the following for their support in the development of this podcast: Joanna Colangelo, Mark Dickinson, Whitney Garrett, Tracy Murray, SYK, and Dr. Elad Levy.

Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks to never miss an episode.

Thank you for supporting the Neuro Innovation Talks podcast!

Special Memorial Episode: John Murray and Dr Nick Hopkins Discuss Multidisciplinary Neuro Innovation

Synopsis: 

In this episode of Biotech 2050, host Alok Tayi explores the world of biotech venture capital with Narayan Chowdhury, Co-Founder of Franklin Park. As a key player in funding the next wave of biotech breakthroughs, Narayan shares how limited partners (LPs) navigate risk, identify high-potential biotech funds, and decide where to allocate billions in capital.

Discover why biotech investing is different from tech VC, the growing role of AI in drug development, and how emerging biotech hubs are shaping the future of innovation. Whether you're a founder, investor, or just biotech-curious, this episode unveils the strategies, challenges, and untapped opportunities that fuel the industry.


Biography:

At Franklin Park, Narayan is responsible for the analysis and evaluation of private equity investment opportunities, monitoring clients’ portfolios and conducting industry research. He is also involved in the development and implementation of Franklin Park’s technology platform, and regularly interacts with clients on investment and portfolio matters.

Prior to Franklin Park, Narayan worked with Hamilton Lane and Public Financial Management.  He is a CFA Charterholder and a member of the CFA Institute. Narayan received a B.A. in Mathematics and Economics from Bucknell University.

Biotech Venture Investing with Narayan Chowdhury, Co-Founder of Franklin Park LLC

In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that’s approaching the complicated and competitive TAVR market.

Chris Newsmaker and Host Tom Salemi also discuss this week’s Newmarker’s Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA.

This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

How an artful pivot and IPO is positioning Anteris Technologies to take on the red hot TAVR space

In this episode of the DeviceTalks Weekly Podcast, it’s a DeviceTalks Team Up. Editorial Director Tom Salemi and Managing Editor Kayleen Brown interview Doug Evans, CEO and President of Lungpacer Medical. Evans shares the tragic reason he vowed to start a company that would help wean patients off ventilators. We’ll hear his success story in the podcast, but join us at DeviceTalks Boston to hear the story behind the AeroPace technologies as Evans will be joined by Lungpacer COO Viral Thakkar and Mike Longo, vice president of product development.

Register to attend DeviceTalks Boston at Boston.DeviceTalks.com. If you missed our early bird rate use the code mentioned in the podcast on March 1 and 2.

Before the DeepDive conversation, we’ll have Mass Device Honcho Chris Newmarker’s Newsmakers - Medtronic, Solventum, FDA layoffs, Boston Scientific, and Teleflex.  

Jim Hammerand, managing editor of Medical Design & Outsourcing, opens with an overview of the magazine’s current Min-Vasive issue. You can find all the articles mentioned at medicaldesignandoutsourcing.com.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Hear Part 1 of Lungpacer Medical’s AeroPace Story; Be part of the conclusion at DeviceTalks Boston

In the kickoff episode of Season 2 of Ortho Innovation Talks, Louie Vogt, Group President of Reconstructive at Enovis, takes us inside the company’s strategic growth in orthopedics. Vogt shares how Enovis has transformed into a major player in the reconstructive space through key acquisitions and bold bets on innovative implant designs.

He discusses the evolution of knee implants, highlighting Enovis’ pioneering work with kinematically driven bearings and the dual pivot knee concept. Vogt also touches on the growing role of robotics and enabling technologies in orthopedic surgery, emphasizing how these advancements are changing the surgeon experience and patient outcomes.

Beyond knees, Vogt explores Enovis’ expansion into foot and ankle reconstruction—a rapidly growing market—and how the company is leveraging M&A and innovation to carve out a competitive edge. As Enovis looks ahead to 2025, Vogt teases major product launches in shoulders, hips, and extremities, signaling another big year for the company.

This conversation comes to you courtesy of our sponsor, Paragon Medical. To learn more about how Paragon Medical can help you bring your device to market faster, visit them at www.paragonmedical.com.

Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

WATCH and LISTEN below, thank you for supporting Ortho Innovation Talks!

Enovis’ Vogt on driving recon growth past $1B w/ M&A, knee breakthroughs and foot & ankle expansion

Das neue Jahr ist da und Signals for Life setzt einen klaren neuen Fokus: Nachwuchs! Dabei geht es uns darum, von Schüler*innen über Bachelor- und Masterstudent*innen bis hin zu Post-Docs zu denken. Nachdem wir uns jahrelang gefragt haben mit welchen Themen wir vor allem junge Menschen erreichen können, wollen wir sie in diesem Jahr einfach selbst zu Wort kommen lassen und bspw. Fragen nachgehen, warum sich eine große Menge an jungen Menschen unter dem Schlagwort Elektrotechnik einen weißen Mann Ü 40 im Blaumann mit Werkzeugkasten vorstellen – dass es sich hier nur um ein irreführendes stereotypes Bild handelt, ist den meisten gar nicht klar! 

In Folge 57 sprechen die Expert*innen Målin Schmidt, Prof. Dr.-Ing. Karsten Seidl und Prof. Dr. Katrin Skerl über ihre eigenen Erfahrungen in Hochschulinitiativen und ihre Motivationen sich im Bereich Nachwuchsförderung und -kommunikation zu engagieren. Dabei skizzieren sie die bisherige Landschaft an Förderungen, Organisationen und anderen Vernetzungsmöglichkeiten und geben Einblicke in deren Angebote. Wir sprechen über das Junge Forum BMT, den Klee-Preis, das VDE Young Net und vieles mehr. In einer Zeit, wo Studienzahlen in einigen MINT-Bereichen sukzessive rückläufig sind, ist es selbstverständlich essenziell wichtig, sich mit der richtigen Ansprache und nötigen Transparenz gegenüber jungen interessierten Personen zu beschäftigen. Auf der einen Seite heißt es demnach mehr Wissenschaftskommunikation und auf der anderen Seite geht es aber auch darum Angebote barrierearm zu gestalten, um so Hürden gering zu halten. Das Format Junges Forum trifft alte Hasen, zeigt einmal mögliche Karrierewege auf und gibt zusätzlich die Möglichkeiten leichter einzusteigen. Hierarchiekonzepte spielen hier kaum eine Rolle und so können die doch sehr unterschiedlichen Zielgruppen voneinander profitieren und lernen. Denn spätestens im Studium ist es wichtig darauf vorzubereiten, welche späteren Berufsmöglichkeiten im Raum sind und dahingehende Vernetzung in Wissenschaft und Wirtschaft bereits zu schaffen und zu festigen. 

https://www.vde.com/de/dgbmt

Fachausschuss Biosignale: https://www.fachausschuss-biosignale.de

Zu Gast: 

Målin Schmidt - https://www.vde.com/de/vde-youngnet/fuer-studierende/fachliche-netzwerke/junge-dgbmt


Prof. Dr. Katrin Skerl - https://www.hs-furtwangen.de/zukunft-verbinden/personen/profil/1415-katrinskerl

Prof. Dr.-Ing. Karsten Seidl – https://www.ims.fraunhofer.de/de/Karriere/Berufseinsteiger-Promotion/Interview-Doktorvater-Seidl.html

Karte mit allen Studienmöglichkeiten BMT im deutschsprachigen Raum 
www.bmt-ausbildung.de
 
Preise der DGBMT (u.a. Förderpreis der DGBMT der "Stiftung Familie Klee")
https://www.vde.com/de/dgbmt/preise-ehrungen
 
Rückblick auf Junges Forum BMT
https://www.vde.com/de/vde-youngnet/fuer-studierende/fachliche-netzwerke/junge-dgbmt/junges-forum-bmt/junges-forum-bmt-rueckblick
 
Ankündigungen Junges Forum 2025
https://bmt2025.ch/programme-abstracts/students-young-researchers
 
Lernsoftware „Unser Herz“
https://blbt.file2.wcms.tu-dresden.de/bme2o/bme2o/unser-herz/lernpaket/lernsoftware-unser-herz/
 
Wissensbasis BMT
https://blbt.file2.wcms.tu-dresden.de/bme2o/
 
VDE YoungNet mit Karte aller VDE Hochschulgruppen und Veranstaltungen für Studierende, Schüler*innen und YoungProfessionals
https://www.vde.com/de/vde-youngnet


Fachausschuss Biosignale: 
https://www.vde.com/de/dgbmt/arbeitsgebiete/fachausschuesse/biosignale-informationsverarbeitung

#57 Nachwuchs: Kommunikation mit Strategie – Wie ist der Stand der Dinge?

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Todd Langevin, president of BIOTRONIK Neuro, a familiar name in medical devices with a new approach to alleviating pain through spinal cord stimulation. Langevin, who has spent his career in neuro devices, gives his assessment of the field today, explaining how it’s exceeded his early expectations.

Just before that Tom talks with Joe Mullings of The Mullings Group and Surgical Robotics Expert Steve Bell about the state of the surgical robotics industry. The trio will talk about current leaders, emerging powers, and how a shift toward cardiac surgeons could change the playing field completely.

But to start, MassDevice Editor Chris Newmarker joins Tom for the Newmarker’s Newsmakers, the leading stories from the pages of MassDevice. This week’s newsmakers include Tariffs, Medtronic, Surgical Robotics, Stryker, and BCI company Paradromics.

Thank you for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

BIOTRONIK Neuro’s Langevin talks power of connected spinal stim; What’s Next in Surgical Robotics

Body Liquid Analysis, Advancing Healthcare with Precision Medicine

Body Liquid Analysis_ Advancing Healthcare with Precision Medicine

Visit www.lifeblood.com/podcast for the full episode!

Marty Gomez - Goodwin's Lifecycle MedTech Practice

Marty Gomez - A Coordinated MedTech Legal Strategy

Listen to the full episode at www.lifeblood.com/podcast

Marty Gomez - MedTech Legal Strategy and Goodwin's Lifecycle Practice

Small biotech companies are facing tough times, shrinking funding and uncertain futures. But beneath the surface, quiet forces of innovation and resilience are rising. This episode explores how biotechs ignite innovation despite economic headwinds, regulatory uncertainty, and fierce competition.

Small Biotechs, Big Decisions is a limited podcast series exploring the challenges and opportunities facing emerging biotech companies, hosted by Daniel Chancellor, VP of Thought Leadership at Norstella, and Claire Riches, VP of Clinical Solutions at Citeline, a leading provider of life sciences data and insights.

View the video series and find out more information here: https://www.citeline.com/biotech

First Sparks: Falling for Innovation in a Harsh Market [2025 Biotech Landscape]

Edited June 6th, reloaded June 7th.
Thursday, June 5th, MBN was On The Road to Delta Township, (SW Lansing metro) as IONETIX Invests $25.75M in Delta Township Facility, Creating 53 High-Tech Jobs and Advancing Lansing’s MedTech Leadership

Expansion includes new cyclotron, advanced isotope lab, and strengthens Lansing’s position as a national MedTech innovation hub

In this video remarks are shared by officials and leaders involved ahead of the ribbon cutting ceremony. Please bear with occasional wind noise on the video's audio. 

Lansing, Mich. (June 6, 2025) — Yesterday, IONETIX, a leader in advanced radiopharmaceutical technologies, is investing $25.75 million to expand its Delta Township facility. The project will add a second cyclotron, and an advanced isotope processing laboratory. The expansion is expected to create 53 high-tech jobs and further accelerate innovation in life sciences and nuclear medicine manufacturing.

“IONETIX’s expansion is creating high-skill, high-value jobs and elevating the Lansing Region within the global medical technology landscape,” said Bob Trezise, president and CEO of the Lansing Economic Area Partnership (LEAP). “LEAP is proud to support this project and the ecosystem of innovative MedTech companies making our region a destination for biomedical research and economic opportunity.” 

IONETIX marked the milestone with a community event at its Delta Township facility, bringing together company leaders, regional partners, and officials from across the state. Speakers included representatives from IONETIX, LEAP, the Michigan Economic Development Corporation (MEDC), and Delta Township. 

Founded in 2009 from technology developed at the MIT Plasma Science and Fusion Center, IONETIX has pioneered the world’s first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 ammonia, one of the most accurate positron emission tomography (PET) imaging agents for detecting coronary artery disease (CAD). The company has also expanded its focus to targeted alpha therapy (TAT), an emerging cancer treatment utilizing high-energy alpha particles to target cancer cells while preserving healthy tissue. 

"Delta Township and the Lansing region offer the ideal environment for IONETIX’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion,” said Kevin J. Cameron, Chief Executive Officer of IONETIX. “We are honored to invest in this community and proud that it is in the forefront of creating diagnostic and therapeutic innovations.”

This expansion aligns with IONETIX’s broader strategy to grow its radiopharmaceutical manufacturing network, advance commercialization of new therapies, and reinforce Michigan's leadership in life sciences and medical technology innovation.

The State of Michigan, through the Michigan Business Development Program, awarded IONETIX $750,000 in incentives to support this expansion, ensuring a strong pipeline of skilled talent and continued innovation in the region.

We are thrilled with the company’s commitment to Michigan and the Lansing community by investing over $25 million to accelerate the efforts to one day cure cancer,” said Matt McCauley, Senior Vice President for Regional Development at the MEDC. "Team Michigan welcomes IONETIX Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan.

» Visit MBN website: www.michiganbusinessnetwork.com/
» Subscribe to MBN’s YouTube: www.youtube.com/channel/UCqNX…
» Like MBN: www.facebook.com/mibiznetwork
» Follow MBN: twitter.com/MIBizNetwork/
» MBN Instagram: www.instagram.com/mibiznetwork/

MBN on the Road | Pure Lansing - LEAP in Delta Twp. for  IONETIX Ribbon Cutting June 5th 2025

This podcast is based on Ottobock Scandinavia’s August newsletter, featuring highlights such as the new Speedhand Solution, the Genu Arexa PCL knee brace, expert tips for Quickchange and Evanto, and invitations to webinars and virtual symposiums.

Newsletter AI version: August 2025 – Inspiring product news, webinars, pro tips and more!

Nach unserem Blick in den Anfang einer Bachelorphase in Folge 61 setzen wir die Reise durch das MINT-Studium an der TU Ilmenau fort – diesmal mit Fokus auf die Forschung. Wie verändert sich das Studium, wenn man tiefer einsteigt? Welche Chancen eröffnet die Spezialisierung – und wie lassen sich Theorie, Praxis und wissenschaftliche Eigenständigkeit verbinden?
Unsere Gäste Luisa und Isabelle berichten von ihren individuellen Wegen in ihrem Studium, von Forschungsprojekten, internationalen Erfahrungen und den besonderen Herausforderungen dieser Studienetappe. Gemeinsam mit Prof. Jens Haueisen sprechen wir außerdem über die Rolle der Biomedizintechnik in der medizinischen Versorgung von morgen, über Karrierechancen und über die Frage, warum gerade Ilmenau für viele ein Ort ist, an dem man Technik nicht nur studieren, sondern wirklich leben kann. Und wir fragen nach, welche Kompetenzen junge MINT-Talente in Zukunft brauchen, um im Spannungsfeld von Technologie und Ethik handlungsfähig zu bleiben.
Eine Folge über Spezialisierung, Forschung, Zukunftsperspektiven – und die Lust, mit Technik einen Unterschied zu machen und deutlich macht: Die Zukunft der Medizin ist digital – aber sie bleibt menschlich. 

https://www.vde.com/de/dgbmt

Fachausschuss Biosignale: https://www.fachausschuss-biosignale.de

Zu Gast: 

Luisa Carillo Villanueva 

Isabelle Saalfeld: https://www.linkedin.com/in/isabelle-saalfeld/?originalSubdomain=ch

Prof. Dr.-Ing. Jens Haueisen: https://www.tu-ilmenau.de/universitaet/fakultaeten/fakultaet-informatik-und-automatisierung/profil/institute-und-fachgebiete/institut-fuer-biomedizinische-technik-und-informatik/bmti/fachgebiete/biomedizinische-technik/institutsleiter-und-fachgebietsleiter-biomedizinische-technik

  
VDE YoungNet mit Karte aller VDE Hochschulgruppen und Veranstaltungen für Studierende, Schüler*innen und YoungProfessionals:

https://www.vde.com/de/vde-youngnet


TU Ilmenau: 
https://www.tu-ilmenau.de

TechnoThek: 
https://www.vdi.de/ueber-uns/vor-ort/landesverbaende/thueringen/technothek-thueringen

#62 MINT im Studium – Bachelor & Forschung: Zukunftsperspektiven aus Ilmenau

Der VDE, eine der größten Technologie-Organisationen Europas, steht seit mehr als 125 Jahren für Innovation und technologischen Fortschritt. Als einzige Organisation weltweit vereint der VDE dabei Wissenschaft, Standardisierung, Prüfung, Zertifizierung und Anwendungsberatung unter einem Dach. Das VDE Zeichen gilt seit mehr als 100 Jahren als Synonym für höchste Sicherheitsstandards und Verbraucherschutz.

Impressum: http://www.vde.com/impressum

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

The Home of Business in Michigan. Get on-demand access to audio programs, articles and resources presented by savvy business leaders and industry experts.

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Ottobock Scandinavia's podcast "Let's talk O&P" is for CPOs, technicians and everyone who works in the O&P industry. We are providing the newest trends, best-practice and educational topics straight to your headphones. Follow us on Instagram ottobock_scandinavia and share your views with us there!

Focus on:
→ Prosthetics
→ Orthotics & Neuromobility
→ Planning, equipping & Materials

For: Healthcare professionals in Scandinavia

New tracks tagged #MedTech